tiprankstipranks
Advertisement
Advertisement
Beam Therapeutics: Buy Rating Reaffirmed as Clinical Momentum Builds and $68 Price Target Remains Unchanged
PremiumRatingsBeam Therapeutics: Buy Rating Reaffirmed as Clinical Momentum Builds and $68 Price Target Remains Unchanged
2M ago
Beam Therapeutics price target lowered to $39 from $40 at Bernstein
Premium
The Fly
Beam Therapeutics price target lowered to $39 from $40 at Bernstein
2M ago
FDA Commissioner Marty Makary resigns
Premium
The Fly
FDA Commissioner Marty Makary resigns
2M ago
Beam Therapeutics rises 10.8%
PremiumThe FlyBeam Therapeutics rises 10.8%
2M ago
Beam Therapeutics: Compelling BEAM-302 Data and Manageable Safety Profile Underpin Buy Rating and Favorable Risk‑Reward
Premium
Ratings
Beam Therapeutics: Compelling BEAM-302 Data and Manageable Safety Profile Underpin Buy Rating and Favorable Risk‑Reward
3M ago
Beam Therapeutics’ risto-cel shows efficacy in Sickle Cell Disease trial
Premium
The Fly
Beam Therapeutics’ risto-cel shows efficacy in Sickle Cell Disease trial
3M ago
Beam Therapeutics Restructures Base-Editing Licensing After Bio Palette Exit
PremiumCompany AnnouncementsBeam Therapeutics Restructures Base-Editing Licensing After Bio Palette Exit
4M ago
Beam Therapeutics Earnings Call Highlights PKU Pivot
Premium
Company Announcements
Beam Therapeutics Earnings Call Highlights PKU Pivot
4M ago
Beam Therapeutics: Advancing Interventional Genetics With Strong Balance Sheet and Multiple Near-Term Catalysts Supporting Buy Rating
Premium
Ratings
Beam Therapeutics: Advancing Interventional Genetics With Strong Balance Sheet and Multiple Near-Term Catalysts Supporting Buy Rating
4M ago

Trending

Name
Price
Price Change
S&P 500
Dow Jones
Nasdaq 100